148 related articles for article (PubMed ID: 15314265)
1. Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?
Windisch M; Hutter-Paier B; Schreiner E; Wronski R
J Mol Neurosci; 2004; 24(1):155-65. PubMed ID: 15314265
[TBL] [Abstract][Full Text] [Related]
2. Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies.
Overk CR; Cartier A; Shaked G; Rockenstein E; Ubhi K; Spencer B; Price DL; Patrick C; Desplats P; Masliah E
Mol Neurodegener; 2014 May; 9():18. PubMed ID: 24885390
[TBL] [Abstract][Full Text] [Related]
3. Extracts from two ubiquitous Mediterranean plants ameliorate cellular and animal models of neurodegenerative proteinopathies.
Briffa M; Ghio S; Neuner J; Gauci AJ; Cacciottolo R; Marchal C; Caruana M; Cullin C; Vassallo N; Cauchi RJ
Neurosci Lett; 2017 Jan; 638():12-20. PubMed ID: 27919712
[TBL] [Abstract][Full Text] [Related]
4. Neuropathology in mice expressing human alpha-synuclein.
van der Putten H; Wiederhold KH; Probst A; Barbieri S; Mistl C; Danner S; Kauffmann S; Hofele K; Spooren WP; Ruegg MA; Lin S; Caroni P; Sommer B; Tolnay M; Bilbe G
J Neurosci; 2000 Aug; 20(16):6021-9. PubMed ID: 10934251
[TBL] [Abstract][Full Text] [Related]
5. Role of synucleins in Alzheimer's disease.
Crews L; Tsigelny I; Hashimoto M; Masliah E
Neurotox Res; 2009 Oct; 16(3):306-17. PubMed ID: 19551456
[TBL] [Abstract][Full Text] [Related]
6. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations.
Li W; West N; Colla E; Pletnikova O; Troncoso JC; Marsh L; Dawson TM; Jäkälä P; Hartmann T; Price DL; Lee MK
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2162-7. PubMed ID: 15684072
[TBL] [Abstract][Full Text] [Related]
7. Novel systemic delivery of a peptide-conjugated antisense oligonucleotide to reduce α-synuclein in a mouse model of Alzheimer's disease.
Leitão ADG; Ahammad RU; Spencer B; Wu C; Masliah E; Rissman RA
Neurobiol Dis; 2023 Oct; 186():106285. PubMed ID: 37690676
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets.
Kwon S; Iba M; Kim C; Masliah E
Neurotherapeutics; 2020 Jul; 17(3):935-954. PubMed ID: 32347461
[TBL] [Abstract][Full Text] [Related]
9. Linking alpha-synuclein properties with oxidation: a hypothesis on a mechanism underling cellular aggregation.
Scarlata S; Golebiewska U
J Bioenerg Biomembr; 2014 Apr; 46(2):93-8. PubMed ID: 24474217
[TBL] [Abstract][Full Text] [Related]
10. Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model.
Hamamichi S; Rivas RN; Knight AL; Cao S; Caldwell KA; Caldwell GA
Proc Natl Acad Sci U S A; 2008 Jan; 105(2):728-33. PubMed ID: 18182484
[TBL] [Abstract][Full Text] [Related]
11. A loss in cellular protein partners promotes α-synuclein aggregation in cells resulting from oxidative stress.
Guo Y; Scarlata S
Biochemistry; 2013 Jun; 52(22):3913-20. PubMed ID: 23659438
[TBL] [Abstract][Full Text] [Related]
12. Special Issue "Neurobiology of Protein Synuclein".
Toni M
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542197
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective Effect of Brazilin on Amyloid β (25-35)-Induced Pathology in a Human Neuroblastoma Model.
Henríquez G; Mendez L; Varela-Ramirez A; Guerrero E; Narayan M
ACS Omega; 2020 Jun; 5(23):13785-13792. PubMed ID: 32566844
[TBL] [Abstract][Full Text] [Related]
14. Exceptional in vivo catabolism of neurodegeneration-related aggregates.
Datki Z; Olah Z; Hortobagyi T; Macsai L; Zsuga K; Fulop L; Bozso Z; Galik B; Acs E; Foldi A; Szarvas A; Kalman J
Acta Neuropathol Commun; 2018 Jan; 6(1):6. PubMed ID: 29378654
[TBL] [Abstract][Full Text] [Related]
15. A Mutual Nexus Between Epilepsy and α-Synuclein: A Puzzle Pathway.
Ali NH; Al-Kuraishy HM; Al-Gareeb AI; Alnaaim SA; Hetta HF; Saad HM; Batiha GE
Mol Neurobiol; 2024 May; ():. PubMed ID: 38703341
[TBL] [Abstract][Full Text] [Related]
16. Misfolded, protease-resistant proteins in animal models and human neurodegenerative disease.
Dickson DW
J Clin Invest; 2002 Nov; 110(10):1403-5. PubMed ID: 12438436
[No Abstract] [Full Text] [Related]
17. Structure-Activity Relationships of Styrylquinoline and Styrylquinoxaline Derivatives as α-Synuclein Imaging Probes.
Nakagawa K; Watanabe H; Kaide S; Ono M
ACS Med Chem Lett; 2022 Oct; 13(10):1598-1605. PubMed ID: 36262393
[TBL] [Abstract][Full Text] [Related]
18. Mass and charge distributions of amyloid fibers involved in neurodegenerative diseases: mapping heterogeneity and polymorphism.
Pansieri J; Halim MA; Vendrely C; Dumoulin M; Legrand F; Sallanon MM; Chierici S; Denti S; Dagany X; Dugourd P; Marquette C; Antoine R; Forge V
Chem Sci; 2018 Mar; 9(10):2791-2796. PubMed ID: 29732065
[TBL] [Abstract][Full Text] [Related]
19. Corrigendum to " Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy Body Disease" [Neurobiology of Disease127 (2019) 163-177].
Spencer B; Trinh I; Rockenstein E; Mante M; Florio J; Adame A; El-Agnaf OMA; Kim C; Masliah E; Rissman RA
Neurobiol Dis; 2024 Feb; 191():106397. PubMed ID: 38216383
[No Abstract] [Full Text] [Related]
20. Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.
Tolmasov M; Djaldetti R; Lev N; Gilgun-Sherki Y
Expert Rev Neurother; 2016 May; 16(5):505-13. PubMed ID: 26959397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
